UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL

Inclusion Criteria: * Meets clinical criteria for leukapheresis or has a leukapheresis product previously collected and stored per recommended guidelines. * Provision of signed and dated consent form from parent or guardian (patients \<18), the patient themselves (\>18), or legally authorized representative (patient \>18 who lack decision-making capacity); Pediatric patients will be included in age-appropriate discussions and assent will be obtained for those \> 7 years of age, when appropriate, according to institutional standards. * Willingness to participate in long term follow up study. * Stated willingness to comply with all study procedures and be available for the duration of the study. * Males OR non-pregnant, non-breastfeeding females. o Patients of child-bearing potential or capable of fathering a child must agree to use highly effective contraception from the time of initial CAR T cell administration though 12 months following the final administration of investigational product. * Aged 31 days to 30 years (inclusive) at time of consent and enrollment. * Acute Lymphoblastic Leukemia (ALL) OR Non-Hodgkin Lymphoma (NHL) of B-cell origin that: * Has confirmed expression of CD19 by flow cytometry, immunohistochemistry (IHC), or both. Cohort One Criteria: * Meets any one of the following conditions: * Relapsed two or more times * Relapsed at any time after allogeneic BMT * Refractory to standard therapy as determined by the treating physician * Meets cr…